Gilead Sciences (GILD) is back in focus after the FDA accepted its supplemental filing for a once-weekly oral Yeztugo tablet for HIV prevention, alongside positive Phase 3 data for a separate once-weekly HIV treatment regimen.

At a share price of $123.76, Gilead Sciences has seen its 30-day share price return decline 7.89% and its 90-day share price return fall 10.39%. Its 1-year total shareholder return of 19.58% and 5-year total shareholder return of 119.41% point to stronger longer-term momentum.

If long-acting HIV treatments interest you, it may also be worth seeing what else is shaping healthcare, starting with 38 healthcare AI stocks

After a weak few months for Gilead Sciences, despite rising profitability and a value score of 5, plus a large gap to some analyst targets and intrinsic estimates, you have to ask: is there real upside here, or is the market already pricing in future growth?

Most Popular Narrative: 3.6% Undervalued

According to the most followed narrative on Gilead Sciences, the fair value of $128.38 sits slightly above the last close at $123.76, which sets up a modest valuation gap for investors to interpret.

Gilead is transitioning from a “single-franchise HIV company” into a multi-platform biopharma with high-probability growth drivers in long-acting HIV prevention and oncology, supported by one of the deepest pipelines in large-cap biotech. Near-term earnings headwinds from acquisition spending sit alongside a catalyst-rich period where multiple late-stage programs and new launches could materially reshape the earnings mix over the next few years.

Curious how this narrative gets from today’s earnings base to that higher fair value? The story leans on accelerating profit growth, shifting margins and a future valuation multiple that reflects a broader, more oncology-heavy Gilead Sciences. The exact mix of revenue growth assumptions, margin structure and pipeline contributions is where things really get interesting.

Result: Fair Value of $128.38 (UNDERVALUED)

However, the Gilead Sciences narrative still faces pressure from acquisition related earnings hits and any setbacks in key HIV or oncology approvals that underpin growth expectations.

Another View on Gilead Sciences Valuation

Multiples tell a slightly different story for Gilead Sciences. The stock trades on a P/E of 16.7x, which is a touch higher than the US Biotechs average of 16.5x, yet below a fair ratio of 31x. That mix hints at both some valuation support and some sector level crowding. Is the real risk here overpaying for growth or underappreciating quality?

Next Steps

The mixed tone around Gilead Sciences, with both risks and rewards in play, means the real question is what you make of the numbers and narratives. If you want to weigh the concerns against the potential yourself, start by looking at the 5 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Gilead Sciences?

If the Gilead Sciences story has you thinking about what else might be worth a closer look, you may want to broaden your watchlist with a few focused sets of ideas.

• Target quality at a reasonable price by scanning companies flagged as potential opportunities through the 45 high quality undervalued stocks.
• Strengthen your income stream by reviewing stocks highlighted in the 8 dividend fortresses.
• Sleep a little easier by checking companies that appear in the 66 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.